PDCD1 and neoplasm: Elevated levels of PD-L1 were found in MSI-H tumours, particularly on tumour-infiltrating immune cells (30), thereby providing a putative biological basis for strong anti-PD-1 therapeutic responses in patients with dMMR/MSI-H tumours (31, 32).